Luye Pharmaceutical's new drug LY03010 may improve treatment...
Luye Pharmaceutical's new drug LY03010 may improve treatment compliance and reduce recurrence in patients with schizophrenia. The company has a strategic layout and superior products in the field of CNS treatment, showing ambition to further develop this field. The superior R&D, clinical registration, supply chain and commercialization capabilities established globally prepare for the global commercialization of new products in the future.
Luye Pharmaceutical (02186) has submitted a marketing application for paliperidone palmitate sustained-release suspension injection (LY03010) to the FDA
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4955
Followers
0
Following
11K
Visitors
Follow